Program
venetoclax
Also written as “Venetoclax”, “ABT-199” and “ABT-199 (Main Cohort)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 3 companies.
Drug pageVenetoclax: every studyAll 486 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 5312 open or running | phase 4since Nov 22, 2021 | Apr 1, 2011 | Nov 2026phase 2 · NCT04895436 |
| Hoffmann-La Rocheits history only | 131 open or running | phase 3since Dec 4, 2013 | Aug 10, 2012 | none ahead |
| Oncotherapeutics | 11 open or running | phase 2since Aug 11, 2023 | Aug 11, 2023 | none ahead |
Also a collaborator on its studies: Johnson & Johnson, Baili-Bio (Chengdu) Pharmaceutical, Roche-Genentech, Merck, Sumitomo Pharma and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Oncotherapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 11, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT06115135 · 39 planned · United States
TargetBeta
“Apoptosis regulator Bcl-2 inhibitor”ChEMBL 37, by rule
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 8 |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 4 |
| surzetoclax | AbbVie | phase 2 | 3 |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 1 |
| surzetoclax | AbbVie | phase 1 | 2 |
| FXS0683 | Fosun Pharma | phase 1 | 1 |
Studies
The one study Oncotherapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06115135Multiple Myeloma · United States | 2 | Recruiting | Apr 30, 2026 | 39 |
How it is read
Names in the registry
- “Venetoclax”, 66 entries
- “ABT-199”, 9 entries
- “venetoclax”, 6 entries
- “ABT-199 (Main Cohort)”, 1 entry
- “ABT-199 (Safety Expansion Cohort)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 21 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 21 studies
- Multiple Myeloma, 10 studies
- Lymphoma, Non-Hodgkin, 7 studies
- Lymphoma, Mantle-Cell, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.